CarT is an expensive treatment, and you are right the cash burn...

CarT is an expensive treatment, and you are right the cash burn is the threat.

Burn this quarter should be down a bit as the GBM ttial has been paused for redesign. But that will hopefully only be temporary.

Potential pivot points with CD17 CarT and NK cells in the next 6 months.

Now if Hopper has used his own shares to leverage other companies, isnt that him still using his own money? How does using shares as collateral cause detriment to others? I do that, to whom should I be apologising? I dont think you have a very good understanding of this.

The good news is Hopper hasn't organised a share buy back with its CR money to help ex directors exit the company at a better price. That was your fella wasnt it? Clever fella to organise that and have shareholders happy about it.